SABCS 2025: Latest developments in multigene testing in early breast cancer

Gustave Roussy International Egypt: Public private partnership model in cancer care

Multimodal AI model augments Oncotype DX in predicting distant recurrence in HR+/HER2 node negative BC

Non-TBI conditioning achieves positive results in MRD-negative CAYA B-ALL undergoing allogeneic HCT

Higher tumour-infiltrating lymphocytes predict better pathologic response in HER2-positive breast cancer

Dasatinib, prednisone, and blinatumomab combination shows promising outcomes in elderly patients with Ph+ ALL

Blinatumomab plus chemotherapy shows manageable toxicity in adults with Ph- B-ALL

Tucatinib added to trastuzumab and pertuzumab improves PFS in first-line HER2-positive metastatic breast cancer

Oncofertility counseling and fertility preservation in premenopausal women with early breast cancer

Aromatase inhibitors improve disease-free survival in HR+/HER2+ early breast cancer: ALTTO 10-year follow-up

Sacituzumab govitecan improves quality of life in untreated advanced TNBC

Pirtobrutinib significantly improves PFS in treatment-naïve CLL/SLL compared to bendamustine plus rituximab